Dalle, Stéphane

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 1,906

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal

Cancer Immunotherapy and BiomarkersInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 412

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

Danlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 300

Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells

Clement, E., Lazar, I., Attané, C., Carrié, L., Dauvillier, S., Ducoux‐Petit, M., Esteve, D., Menneteau, T., Moutahir, M., Le Gonidec, S., et al. (2020) · The EMBO Journal

Extracellular vesicles in diseaseCancer, Lipids, and Metabolism

Cited by 240

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 150

Clinical and Sociodemographic Characteristics Associated With Thick Melanomas: A Population-Based, Case-Case Study in France

Grange, F., Barbe, C., Aubin, F., Lipsker, D., Granel-Brocard, F., Velten, M., Dalac, S., Truchetet, F., Michel, C., Mitschler, A., et al. (2012) · Archives of Dermatology

Cutaneous Melanoma Detection and Managementmelanin and skin pigmentation

Cited by 29

Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.

Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A. M., Lichinitser, M., Khattak, M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 14